Capecitabine added after surgery for high-risk ER-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and age 18 to 70.
- You finished radical breast surgery, and testing showed ER and/or PR positive and HER2 negative.
- Your cancer is considered “high risk” by specific features like many lymph nodes, a large/high-grade tumor, or remaining disease after chemotherapy.
- You have not had treatment for this current breast cancer before joining the study.
- You are well enough to do normal activities (ECOG 0–1) and your blood/organ tests are within allowed ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This trial studies whether a low-dose “metronomic” chemotherapy medicine (capecitabine) added to standard hormone therapy can reduce breast cancer coming back. It is for people with hormone-receptor–positive, HER2-negative breast cancer after surgery and chemo.
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
This study tests whether adding utidelone (an investigational drug) to capecitabine (a standard chemo pill) after surgery can reduce the chance of breast cancer returning in patients with triple-negative breast cancer who still had cancer cells after neoadjuvant chemotherapy. Participation could help improve your treatment plan to lower the risk of recurrence.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.